MOH closely monitoring US tariffs, focusing on medical devices, pharmaceutical products
Health Minister Datuk Seri Dr Dzulkefly Ahmad said that although Trump had previously indicated an intention to exempt pharmaceuticals from these tariffs, recent developments suggest otherwise.
"Some of the announced tariffs remain unclear, and with Trump's unpredictability, we must remain vigilant. It is crucial for me, as the health minister, to stay attentive to these two matters," he told a press conference after opening the state-level 2025 Madani Afiat Programme in Tunjong here today.
He was responding to questions about the potential impact of the US tariffs on the nation's healthcare supply chain.
Dzulkefly said the ministry was also making early preparations to find alternative markets and sources to ensure the continuity of the country's health supply is not affected.
On April 2, Trump announced a series of reciprocal tariffs imposed on many countries, including 24 per cent on imports of goods from Malaysia, but this has been postponed for 90 days.
Meanwhile, regarding the ban on the sale of electronic cigarette (vape) products by the Terengganu government effective Aug 1, he said the ministry was determined to implement comprehensive regulation on vape products with the gazette of the Smoking Products Control for Public Health Act 2024.
He said the act, which functions as a stand-alone legislation, would serve as a strong foundation for regulating all aspects related to smoking products, including their registration, sales, advertising, and nicotine content.
"Our approach is to enforce strict regulation. Sales to minors will be completely prohibited, and stringent controls will be in place to ensure there is no room for any form of leniency," he said.
He said the state government holds an important responsibility through its authority to deny business licences to entrepreneurs selling smoking products.
He viewed the collaboration by the state government as a positive step towards safeguarding public health.
The Terengganu government announced it will enforce a ban on the sale of vape products at all business premises across the state starting Aug 1.
Terengganu Local Government, Housing and Health Committee Chairman Datuk Wan Sukairi Wan Abdullah was reported as saying that the enforcement is a proactive move by the state government to curb the sale and use of vape products, which pose health risks, particularly to the younger generation.
– Bernama
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
28 minutes ago
- Malay Mail
Malaysians, beware of unlicensed beauty doctors: Court awards RM800,000 compensation over PJ clinic's botched breast fillers
Sessions Court awarded RM800,000 in exemplary damages to a woman harmed by breast filler injections at an unlicensed Petaling Jaya beauty clinic, to deter unqualified doctors and clinics It said Malaysians should check if those giving them beauty treatments are actually doctors and whether they have Health Ministry-issued qualification to carry out aesthetic treatments It was also determined that consent form signed by patients are invalid, if the doctor did not tell the patient that they are not qualified to carry out the procedure KUALA LUMPUR, July 30 — Malaysians should make sure to ask doctors if they have the Health Ministry's licence to carry out aesthetic and beauty treatments on them, the Sessions Court in Kuala Lumpur has said in its RM800,000 decision over a breast filler injection procedure. In this medical negligence case, Sessions Court judge Saifullah Bhatti ordered a doctor who did not have the licence, a Petaling Jaya beauty clinic found to be unlicensed, and the beauty clinic's owner, to pay RM800,000 in exemplary damages to a woman over the injection of fillers into her breasts. In this case, the woman — identified only as R for privacy purposes — had experienced pain and swelling after the breast filler injections in 2020. This resulted in her later visiting multiple other doctors, undergoing two MRI scans, and undergoing three surgeries in 2021 and 2024 to remove the fillers, as well as other treatments. With the Sessions Court able to handle cases involving a maximum RM1 million amount, judge Saifullah yesterday said the compensation amount of RM800,000 would send a strong message to doctors in Malaysia to get their qualifications and only do medical procedures that are covered by their licences. The Sessions Court noted that exemplary damages are meant to raise awareness to the public on the issues in a case, and to make an example out of those being sued and to deter them from repeating the same actions they were sued for. The Sessions Court noted that the High Court had in another case in November 2024 awarded RM100,000 in exemplary damages to deter 'beauty clinics which have mushroomed nationwide offering beauty aesthetics surgeries' from performing procedures that are not covered in their licences. The Sessions Court said there is increasingly alarming news of more and more doctors being caught for performing procedures without licence: 'In many cases around the world and not just in Malaysia, patients are sometimes left to die bleeding on the operating table.' Even with the High Court having awarded RM100,000 in the 2024 case, there continues to be news of such rampant doctors, and the Sessions Court judge noted that the RM100,000 sum has not been potent enough to deter such doctors. In Malaysia, the Health Ministry's guidelines require doctors to get the ministry's 'Letter of Credentialling and Privileging' (LCP) or qualification before they can carry out aesthetic procedures — including breast filler injections — on patients. In R's case, the Sessions Court judge said the RM800,000 exemplary damages award was necessary to let Malaysians know they should check on doctors carrying out beauty treatments on them. While anyone can be blamed for not asking basic questions 'such as whether the person treating them is in the first place a doctor', the Sessions Court judge said it is harder to expect the public to know that the doctor must also have an LCP to carry out the aesthetic procedure on them. 'As such, in deciding this case, and in granting exemplary damages, it is hoped that the general public is more aware of this issue and they should now be on notice to take all necessary precautions when consulting doctors for aesthetic procedures including asking all the right questions regarding your doctors qualifications – specifically whether they have the LCP,' the judge said in a 66-page judgment released yesterday. The judge said the RM800,000 sum was justified as the case involves 'public health and safety and holding recalcitrant doctors accountable to medical law, regulations and ethics', and that it was a fair amount that should remind all doctors to get their qualifications and to stay within the limits of their certifications and their LCP. In arriving at the RM800,000 figure, the judge had noted the facts where the doctor did not have an LCP; and that the doctor had failed the examination for the LCP but her 'niat tertunda' or her intention to resit for the examination was postponed because of the movement control orders during the Covid-19 pandemic. The judge also noted that the doctor had taken her lack of the LCP more lightly than she should have as she tried to cite other inapplicable course certificates to insist she was qualified; and that the doctor had misrepresented to R that she would be injected with 100 per cent pure hyaluronic acid fillers but instead injected her with a filler which was lab-tested to be 'primarily composed of silicone'. The judge said the doctor had gone on to perform a drainage procedure on R without an LCP; and that the aesthetic centre and its owner had allowed the doctor to carry out those two procedures on R without an LCP; and that there was no proof that the aesthetic centre and its owner had Health Ministry-required licence to carry out the business. Ultimately, the Sessions Court awarded the woman R with compensation totalling RM919,009.60 in the form of RM800,000 exemplary damages, RM85,000 in general damages for her pain and suffering; and RM34,009.60 in special damages; and also awarded RM25,000 in costs to her. What R's lawsuit was about and what the court decided In her lawsuit filed in April 2023 at the Sessions Court in Kuala Lumpur, the patient R had sued Dr S, the aesthetic centre's owner SHA, and the aesthetic centre's company F to claim for compensation. R's lawsuit claimed that Dr S was negligent by carrying out an aesthetic medical procedure without proper accreditation or licensing and failing to comply with the accepted standard of care by injecting the wrong filler into R's breasts. R claimed that the other two sued were negligent by appointing an unlicensed medical practitioner to perform the procedure and for failing to meet the appropriate standard of care that was expected of them as a medical facility. The Sessions Court found Dr S to be negligent as she performed the procedure on R without the LCP accreditation, also noting that Dr S had failed to disclose to R that she was not legally qualified to perform the procedure. Dr S was also found liable, as R would not have suffered the injuries if she had not used a filler that was later found to be primarily composed of silicone. While Dr S claimed that R had accepted the risks by signing a consent form before the breast filler procedure, the Sessions Court said the patient could not have consented to what had happened to her as she had consented to a pure HA injection instead of a mainly-silicone injection. 'When a doctor performs a procedure without disclosing the fact they are not qualified (such as what happened in this case), any consent obtained under that present is invalid,' the judge said, having noted that a previous High Court decision had found that such failure would undermine a patient's ability to make informed decisions about their treatment. The Sessions Court also found SHA and F to be negligent, noting that the beauty clinic's claimed Petaling Jaya City Council licence was irrelevant as it would only be a local authority's permit to run a healthcare business and is not a valid Health Ministry-required permit to perform medical aesthetics procedures. The Sessions Court said the man SHA is just as liable as Dr S as they were business partners; and the beauty clinic's company F is a healthcare facility which had not shown any accreditation or licensing required under the Private Healthcare Facilities And Services Act 1998 and that it was not qualified to 'play host to what was essentially an unlicensed and therefore illegal business'. R was represented by lawyers Dayang Roziekah Ussin, Abu Daud Abd Rahim and Nik Amalia Suraya Nik Muhammad; while the three sued were represented by lawyer Fakhrul Azman Abu Hasan.
New Straits Times
28 minutes ago
- New Straits Times
Japan's Nikkei treads water as central bank meetings, tariff deadline loom
TOKYO: Japan's Nikkei share average ended morning trade flat on Wednesday after spending most of the session slightly lower, as investors braced for a three-day period that will see policy decisions from the Federal Reserve and Bank of Japan, followed by US President Donald Trump's deadline for trade deals. The Nikkei entered the midday break little changed at 40,682.14. Of the index's 225 components, 148 rose and 77 fell. The broader Topix rose 0.35 per cent. The Fed sets rates on Wednesday, and while policymakers are widely expected to stand pat, investors will be watching closely for signs that an interest rate cut may be on the way later this year. Similarly, the BOJ is seen keeping policy steady on Thursday, but markets will search for clues on when the central bank is likely to resume rate hikes. On Friday, most US trade partners that have not agreed deals with Washington will receive higher tariff rates. "There are still a lot of uncertainties over tariffs, and that's going to limit the upside for stocks," said Maki Sawada, an equities strategist at Nomura Securities. As a result, "there's no particular sense of direction" in Japanese stock trading currently, she said. Airline ANA Holdings fell 3.8 per cent to be the Nikkei's biggest percentage decliner following its earnings report after the market closed on Tuesday. Earnings also weighed on chip-testing equipment maker Advantest, which slipped 1.8 per cent. Sumitomo Pharma surged nearly 16 per cent to be the biggest percentage gainer.
New Straits Times
28 minutes ago
- New Straits Times
Palm opens higher on strong Dalian oils, crude oil prices
KUALA LUMPUR: Malaysian palm oil futures inched higher on Wednesday, tracking stronger rival Dalian oils and crude oil prices, though weaker Chicago soyoil capped the gains. The benchmark palm oil contract for October delivery on the Bursa Malaysia Derivatives Exchange gained 17 ringgit, or 0.4 per cent, to 4,271 ringgit (US$1,008.98) a metric ton in early trade. The contract rose 0.28 per cent in the previous session. Dalian's most-active soyoil contract rose 0.83 per cent, while its palm oil contract added 0.52 per cent. Soyoil prices on the Chicago Board of Trade were down 0.19 per cent. Palm oil tracks price movements of rival edible oils, as it competes for a share of the global vegetable oils market. Oil prices ticked up in early trading after rising more than 3 per cent in the previous session as potential supply shortages came into focus after US President Donald Trump gave Moscow an abbreviated deadline toward ending the war in Ukraine. Stronger crude oil futures make palm a more attractive option for biodiesel feedstock. European Union soybean imports for the 2025/26 season that began in July reached 736,447 million metric tons by July 27, down 37 per cent from the same period a year earlier while palm oil imports fell by 53 per cent to 118,863 million tons, the European Commission data showed. Indian importers have bought a record 150,000 metric tons of soyoil from China in rare purchases, as a supply glut prompted Chinese crushers to sell at a discount to India's traditional suppliers from South America, four trade sources said. The ringgit, palm's currency of trade, weakened 0.05 per cent against the dollar, making the commodity slightly cheaper for buyers holding foreign currencies. Asian stocks rose modestly on Wednesday, with investors cautious after trade talks between the US and China ended without any substantive agreement and ahead of the Federal Reserve's policy announcement.
